Ra Pharma Reports Third Quarter 2016 Financial Results And Provides Corporate Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ra Pharmaceuticals (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, today announced financial results for the three months ended September 30, 2016 and provided an update on recent corporate and clinical developments.